Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Halozyme Therapeutics, Inc. - Common Stock (NQ: HALO ) 48.13 +0.10 (+0.21%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 946,090 Open 47.60 Bid (Size) 47.50 (1) Ask (Size) 48.47 (1) Prev. Close 48.03 Today's Range 47.56 - 48.26 52wk Range 33.15 - 65.53 Shares Outstanding 142,334,900 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 9 Analysts Have This To Say About Halozyme Therapeutics December 18, 2024 Via Benzinga Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock? December 18, 2024 Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill Performance YTD +28.72% +28.72% 1 Month -0.70% -0.70% 3 Month -15.52% -15.52% 6 Month -8.08% -8.08% 1 Year +29.56% +29.56% More News Read More Looking for growth without the hefty price tag? Consider NASDAQ:HALO. December 16, 2024 Via Chartmill In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. December 13, 2024 Via Chartmill (HALO) - Analyzing Halozyme Therapeutics's Short Interest December 11, 2024 Via Benzinga Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook November 22, 2024 Via Benzinga Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views November 20, 2024 Via Benzinga Looking Into Halozyme Therapeutics's Recent Short Interest November 05, 2024 Via Benzinga A Look Ahead: Halozyme Therapeutics's Earnings Forecast October 30, 2024 Via Benzinga Unveiling 12 Analyst Insights On Halozyme Therapeutics October 25, 2024 Via Benzinga While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. November 22, 2024 Via Chartmill NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. November 22, 2024 Via Chartmill Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion November 15, 2024 Via Benzinga Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday November 01, 2024 Via Benzinga Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. October 22, 2024 Via Chartmill Despite its growth, NASDAQ:HALO remains within the realm of affordability. October 11, 2024 Via Chartmill Despite its impressive fundamentals, NASDAQ:HALO remains undervalued. October 10, 2024 Via Chartmill Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket November 01, 2024 Via Benzinga Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. November 01, 2024 Via Chartmill 12 Health Care Stocks Moving In Thursday's After-Market Session October 31, 2024 Via Benzinga Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. October 31, 2024 Via Chartmill A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts October 04, 2024 Via Benzinga NASDAQ:HALO is showing good growth, while it is not too expensive. September 19, 2024 Via Chartmill NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. September 19, 2024 Via Chartmill Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
